We provide answers, so you can focus on care
We’re moving exome and genome from specialized tests to standard of care, improving patients’ lives by building towards a future where we can sequence DNA once and analyze the results for a lifetime.
We’re a leader in genomics, with over 400,000 clinical exome and genome tests interpreted and delivered. We offer premier expertise in exome sequencing for pediatric conditions and rare and ultra-rare genetic diseases.
Centrellis®, our proprietary health intelligence platform, integrates digital tools with artificial intelligence, allowing us to ingest and synthesize clinical and genomic data to deliver better health insights.
With one of the world’s largest rare disease data sets, we’re poised to accelerate the use of genomics and leverage large-scale clinical data to enable precision medicine as the standard of care.
GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
Mar 20, 2023
Genome Sequencing and Interpretation Services Progressing Quickly for 1,000 Newborns Enrolled in Study to Date; On Track to Support up to 100,000 Study Participants in Next Four Years
GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray
March 16, 2023
New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing’s role in shortening the diagnostic odyssey
GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 14, 2023
Financial results are in line with previously announced preliminary 2022 results; Reiterating 2023 guidance, including total revenue of $205-220 million